- Report
- February 2018
- 85 Pages
Global
From €5789EUR$5,950USD£4,959GBP
- Report
- March 2022
- 80 Pages
Global
From €739EUR$760USD£633GBP
€924EUR$950USD£792GBP
- Report
- March 2022
- 300 Pages
Global
From €4865EUR$5,000USD£4,168GBP
- Report
- August 2022
- 118 Pages
Global
From €4622EUR$4,750USD£3,959GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2676EUR$2,750USD£2,292GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2676EUR$2,750USD£2,292GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2676EUR$2,750USD£2,292GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2676EUR$2,750USD£2,292GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2676EUR$2,750USD£2,292GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2676EUR$2,750USD£2,292GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2676EUR$2,750USD£2,292GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2676EUR$2,750USD£2,292GBP
- Drug Pipelines
- January 2023
- 30 Pages
Japan
From €2676EUR$2,750USD£2,292GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2676EUR$2,750USD£2,292GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2676EUR$2,750USD£2,292GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2676EUR$2,750USD£2,292GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2676EUR$2,750USD£2,292GBP
- Report
- January 2022
- 200 Pages
Global
From €7297EUR$7,500USD£6,251GBP
- Report
- January 2022
- 200 Pages
Global
From €7297EUR$7,500USD£6,251GBP
- Report
- January 2022
- 60 Pages
Global
From €3843EUR$3,950USD£3,292GBP
The Rheumatoid Arthritis Drug market is a subset of the Immune Disorders Drugs market. It is composed of drugs used to treat rheumatoid arthritis, an autoimmune disorder that causes inflammation of the joints. These drugs are used to reduce inflammation, pain, and stiffness, as well as to prevent joint damage. They can be divided into two categories: disease-modifying antirheumatic drugs (DMARDs) and biologic response modifiers (BRMs). DMARDs are used to slow the progression of the disease, while BRMs are used to reduce inflammation and pain.
The Rheumatoid Arthritis Drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, and Roche. Show Less Read more